 NeuBase Therapeutics, Inc. NBSE, a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today the closing of its previously announced underwritten public offering of 6,037,500 shares of its common stock inclusive of 787,500 shares that were sold pursuant to the underwriters full exercise of their option to purchase additional shares of NeuBases common stock, at a price to the public of 6.00 per share. The net proceeds to NeuBase from the offering are expected to be approximately 33.3 million, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by NeuBase. NeuBase intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. 